Exozymes (EXOZ) Competitors $10.31 -0.13 (-1.25%) As of 09:39 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock EXOZ vs. SLRN, CADL, DRUG, AVIR, PROK, ACB, SEPN, IMMP, MNPR, and PRMEShould you be buying Exozymes stock or one of its competitors? The main competitors of Exozymes include Acelyrin (SLRN), Candel Therapeutics (CADL), Bright Minds Biosciences (DRUG), Atea Pharmaceuticals (AVIR), ProKidney (PROK), Aurora Cannabis (ACB), Septerna (SEPN), Immutep (IMMP), Monopar Therapeutics (MNPR), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Exozymes vs. Acelyrin Candel Therapeutics Bright Minds Biosciences Atea Pharmaceuticals ProKidney Aurora Cannabis Septerna Immutep Monopar Therapeutics Prime Medicine Exozymes (NASDAQ:EXOZ) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Which has stronger valuation & earnings, EXOZ or SLRN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExozymesN/AN/AN/AN/AN/AAcelyrinN/AN/A-$381.64M-$2.50-1.03 Does the media refer more to EXOZ or SLRN? In the previous week, Exozymes had 2 more articles in the media than Acelyrin. MarketBeat recorded 3 mentions for Exozymes and 1 mentions for Acelyrin. Acelyrin's average media sentiment score of 0.89 beat Exozymes' score of 0.30 indicating that Acelyrin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exozymes 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acelyrin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EXOZ or SLRN more profitable? Exozymes' return on equity of 0.00% beat Acelyrin's return on equity.Company Net Margins Return on Equity Return on Assets ExozymesN/A N/A N/A Acelyrin N/A -44.12%-39.02% Do institutionals and insiders hold more shares of EXOZ or SLRN? 87.3% of Acelyrin shares are held by institutional investors. 13.6% of Acelyrin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor EXOZ or SLRN? Acelyrin received 16 more outperform votes than Exozymes when rated by MarketBeat users. CompanyUnderperformOutperformExozymesN/AN/AAcelyrinOutperform Votes1655.17% Underperform Votes1344.83% Do analysts rate EXOZ or SLRN? Acelyrin has a consensus target price of $9.60, indicating a potential upside of 271.37%. Given Acelyrin's stronger consensus rating and higher possible upside, analysts plainly believe Acelyrin is more favorable than Exozymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exozymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Acelyrin 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 SummaryAcelyrin beats Exozymes on 7 of the 10 factors compared between the two stocks. Remove Ads Get Exozymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetricExozymesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.27M$2.97B$5.54B$7.49BDividend YieldN/A1.53%5.35%4.04%P/E RatioN/A30.4323.2518.07Price / SalesN/A383.26361.2686.83Price / CashN/A168.6838.1634.64Price / BookN/A3.646.493.99Net IncomeN/A-$72.06M$3.21B$247.18M7 Day Performance3.06%-10.59%-6.42%-6.42%1 Month Performance-38.26%-16.74%-0.68%-7.44%1 Year PerformanceN/A-30.77%6.05%-4.31% Exozymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZExozymesN/A$10.31-1.2%N/AN/A$64.46MN/A0.0029Gap UpSLRNAcelyrin2.9811 of 5 stars$2.74+9.2%$9.60+250.4%-61.1%$252.78MN/A-1.11135High Trading VolumeCADLCandel Therapeutics2.2459 of 5 stars$5.31-4.7%$21.00+295.5%+212.5%$250.82M$120,000.00-3.0760Gap DownDRUGBright Minds Biosciences1.9147 of 5 stars$35.31-2.2%$84.33+138.8%+2,487.5%$248.72MN/A-207.69N/AGap DownAVIRAtea Pharmaceuticals2.5375 of 5 stars$2.88+1.1%$6.88+138.9%-25.6%$246.31MN/A-1.3970Gap DownPROKProKidney1.4426 of 5 stars$0.84+1.2%$5.00+495.5%-52.3%$245.78M$76,000.00-1.533Gap DownACBAurora Cannabis0.2846 of 5 stars$4.47+2.3%N/A-40.5%$245.66M$320.81M89.421,340Gap DownSEPNSepterna1.9821 of 5 stars$5.49+9.4%$33.00+501.1%N/A$243.77M$981,000.000.00N/AGap DownIMMPImmutep1.5058 of 5 stars$1.67-5.6%$8.50+409.0%-36.1%$243.08M$5.14M0.002,021Gap DownMNPRMonopar Therapeutics2.0858 of 5 stars$38.53+15.3%$44.00+14.2%+977.6%$235.11MN/A-19.5610Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownPRMEPrime Medicine2.3033 of 5 stars$1.79+0.3%$13.38+647.2%-72.2%$234.78M$2.98M-0.87234Gap Down Remove Ads Related Companies and Tools Related Companies Acelyrin Competitors Candel Therapeutics Competitors Bright Minds Biosciences Competitors Atea Pharmaceuticals Competitors ProKidney Competitors Aurora Cannabis Competitors Septerna Competitors Immutep Competitors Monopar Therapeutics Competitors Prime Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exozymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exozymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXOZ Stock Free EXOZ Stock Alerts